The DOI matches its Crossref record.
2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Abstract
PURPOSE: Because of the need to identify effective new agents in the treatment of non-Hodgkin's lymphoma and because of the high activity of the purine analog 2-chlorodeoxyadenosine (2-CdA) against chronic lymphocytic leukemia and hairy cell leukemia, a phase II trial of 2-CdA was initiated in patients with low-grade lymphocytic lymphomas. PATIENTS AND METHODS: Forty patients with low-grade lymphocytic lymphomas including diffuse small lymphocytic, follicular small-cleaved, and follicular mixed histologies were enrolled onto the study. Conventional therapies had failed in all patients, and six patients had lymph node biopsies showing evidence of histologic evolution to a higher-grade lymphoma. A total of 107 courses of 2-CdA were administered. There were 27 males and 13 females. The median age was 59 years (range, 37 to 80 years). Patients had received a median of three prior therapies (range, one to six therapies). RESULTS: An overall response rate of 43% was achieved, with eight patients experiencing complete responses (CRs) and nine patients experiencing partial responses (PRs). The duration of responses ranged from 1 to greater than 33 months without maintenance therapy (median duration of response, 5 months). Histology and prior therapy history did not seem to correlate with responses. Significant toxicity was limited to bone marrow suppression; 18% of patients developed neutropenia, and 30% developed thrombocytopenia. CONCLUSIONS: This phase II trial demonstrates that 2-CdA is an effective antilymphocyte, antineoplastic agent with significant activity as a single agent in patients with recurrent or refractory low-grade lymphocytic lymphoma. Responses were achieved with an acceptable toxicity profile. Further trials of this agent in previously untreated patients and in combination regimens are indicated and will be developed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Robertson, L., Chubb, S., Meyn, R., Story, M., Ford, R., Hittelman, W., & Plunkett, W. (1993) · Blood · doi:10.1182/blood.v81.1.143.143 · Cited by 290
Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., Spies, S., Bartlett, N. L., Schilder, R. J., Murray, J. L., Saleh, M., Allen, R. S., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4336 · Cited by 264
Infectious and immunosuppressive complications of purine analog therapy.
Cheson, B. D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.9.2431 · Cited by 260
Lowenthal, R. M., & Eaton, K. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70378-6 · Cited by 104
Metadata
- Authors
- Kay, A. C., Saven, A., Carrera, C. J., Carson, D. A., Thurston, D., Beutler, E., & Piro, L. D.
- Venue
- Journal of Clinical Oncology
- Published
- 1992-03
- Volume
- 10
- Issue
- 3
- Pages
- 371-377
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1792577025
- Cited by
- 166
- References
- 0
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. https://app.cochat.ai/papers/10.1200/jco.1992.10.3.371
- The paper
- Kay, A. C., Saven, A., Carrera, C. J., Carson, D. A., Thurston, D., Beutler, E., & Piro, L. D. (1992). 2-Chlorodeoxyadenosine treatment of low-grade lymphomas. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1992.10.3.371
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.